Minimal residual disease: a key determinant of ALL treatment response
Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker in predicting patient outcomes. MRD can aid in tailoring therapies a...
Author: VJOncology
Added: 05/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Improving response to ALL therapies
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses the novel and interesting approaches for first-line therapy, in acute lymphoblastic leukemia...
Author: VJOncology
Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Challenges with the identification of ALL subtypes
Finding the right treatment for a specific subset of acute lymphoblastic leukemia (ALL) requires a correct diagnosis, but there are many challenges that clinicians face when trying to implement precis...
Author: VJOncology
Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Overcoming the issues with clinical trial recruitment
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the importance of collaborating with other trial groups that are focusing on acute leukemias by joining efforts with o...
Author: VJOncology
Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Midostaurin: the first drug to receive approval for AML since 2000
Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In this interview, Arnold Ganser, MD, from the Hannover Medical School, Hanno...
Author: VJOncology
Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Finding the right targets for CAR T-cell therapy in AML
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, expla...
Author: VJOncology
Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts
The devastating effects of relapsed or refractory AML
Dealing with patients with refractory acute myeloid leukemia (AML) or with those who have relapsed, is challenging, and stem cell transplantation is one of the few therapies that can be offered in the...
Author: VJOncology
Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts
An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany talks about his experience of the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest,...
Author: VJOncology
Added: 05/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Stephan A. Grupp, MD, PhD - Realizing the Promise of CAR-T Cell Therapy for Leukemia and Lymphoma: Implications for Long-Term Care in the Era of Stem Cell Transplantation
Realizing the Promise of CAR-T Cell Therapy for Leukemia and Lymphoma: Implications for Long-Term Care in the Era of Stem Cell Transplantation (Source: PeerView CME/CE Audio Podcast - Immunology)
Source: PeerView CME/CE Audio Podcast - Immunology - May 11, 2018 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Managing disease relapse in transplant patients with AML
Disease relapse is a significant cause of transplant failure in patients with acute myeloid leukemia (AML). Talking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meet...
Author: VJHemOnc
Added: 05/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 11, 2018 Category: Cancer & Oncology Source Type: podcasts
The role of Cure Leukemia in improving access to clinical trials for patients
Cure Leukemia is a leading center for the development of new drug and transplant treatments for patients with hematological cancers. Its aim is to improve the access to the latest clinical trials for ...
Author: VJHemOnc
Added: 05/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities
Paul G. Richardson, MD, explains Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Velocity Vlog: Transforming the Diagnosis and Treatment of CLL
Dramatic progress has been made in our understanding of the clinical, biological and molecular heterogeneity of chronic lymphocytic leukemia (CLL). Despite this, treatment challenges remain, particula...
Author: imedex
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Giving attention to the needs and voices of bone and marrow transplant patients
Blood and bone marrow transplantation continues to experience breakthroughs, with the role of the patient becoming increasingly important. In this talk, Anita Waldmann from the Leukaemia Patient-Suppo...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
The challenges of treating plasma cell leukemia
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia, and can present de novo or following the early symptoms of plasma cell myeloma. Patients with PCL tend to present with aggres...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
